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Abstract
Background: The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract was designed
to assess the impact of a multivitamin-mineral supplement on age-related cataract. Trial results showed evidence
of a beneficial effect of the supplement on all types of cataract combined, opposite effects on two of the three
types of cataract (beneficial for nuclear opacities and harmful for posterior sub-capsular opacities) and no
statistically significant effect on cortical opacities. No treatment recommendations were made. A post-trial survey
was conducted on 817 surviving elderly participants to assess their satisfaction, their understanding of treatment
assignment to supplement or placebo and the success of masking.
Methods: Trial results were communicated by letter and the level of satisfaction and of understanding of the
results was assessed by a questionnaire. Participants were offered the option of being unmasked: a second
questionnaire was administered to this subset to assess their understanding of the randomisation process and the
success of masking.
Results: 610 participants (74.7%) responded to the survey:
94.6% thought the description of the results was “very clear” or “quite clear”, 5.4% “not clear” or “do not know";
89.8% considered the results “very interesting” or “quite interesting”, 10.2% “not interesting” or “do not know";
60.3% expressed “satisfaction”, 17.2% “both satisfaction and concern”, 2.6% “concern”, 19.9% “indifference” or “do
not know”.
480 participants (78.7%) accepted the offer to be unmasked to their treatment assignment: 395 (82.3%) recalled/
understood the possibility of assignment to vitamins or placebo, 85 (17.7%) did not. 68 participants (17.2%)
thought they had taken vitamins (79.4% were correct; p = 0.0006), 47 (11.9%) thought they had taken placebo
(59.6% were correct; p = 0.46) and 280 (70.9%) declared they did not know.
Conclusions: The results were made difficult to explain to study participants by the qualitatively different effect of
treatment on the two most visually significant types of cataract. Although the study did not lead to a
recommendation to use the dietary supplement, the vast majority of participants reported satisfaction after they
received the results but almost 20% of the participants expressed some concern. Masking to treatment assignment
was successful in the majority of participants.
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The Italian-American Clinical Trial of Nutritional Sup-
plements and Age-Related Cataract (CTNS) is a 13-year
individually-randomised, double-masked, single-centre,
placebo-controlled trial designed to investigate whether
adding a daily multivitamin-mineral supplement to the
diet of a generally well-nourished, supplement-naïve
population could affect the onset or progression of age-
related cataract [1]. One thousand and twenty residents
of Parma, Italy, aged 55 to 75 years and with no or early
cataract, were randomly assigned to treatment with a
daily multivitamin-mineral tablet or a placebo. Partici-
pants were treated and followed for an average of
9.0 +/- 2.4 years, from January 1996 to May 2007, with
few losses to follow-up and excellent compliance with
medication assignment, as assessed by pill count and
vitamin plasma levels. Participation involved 2 baseline
visits and a maximum of 20 follow-up visits at six
month intervals that included: eye examination with
visual acuity measurement, pupillary dilation and lens
photography, anthropometric measurements, interviews
and blood collections.
Use of the dietary supplement appeared to have a ben-
eficial effect on any cataract (all types of cataract com-
bined) and on pure nuclear cataract; a harmful effect
was observed on posterior sub-capsular cataract and no
statistically significant effect was observed on cortical
cataract and on important functional end-points (visual
acuity or cataract surgery). These findings, in particular
the opposite effects on the two most visually significant
cataract types, prevented us from making recommenda-
tions about use of one-a-day multivitamin-mineral sup-
plements to affect the risk of cataract development [2].
The Steering Committee unanimously decided to share
the results with CTNS participants even though they
were difficult to convey and there was some risk of gen-
erating misunderstandings. Communicating the results
of a study to participants is a generally accepted practice
in clinical trials [3], but sometimes participants do not
wish to know the results [4,5] nor to be unmasked to
their treatment assignment and may even react nega-
tively [6]. Little is known about the opinions and expec-
tations of participants on sharing the results of a study
such as CTNS, which involved an intervention with
essentially no side effects and a condition (cataract) that
could be effectively treated with surgical intervention.
This paper describes the methodology used to share the
results with CTNS participants and the findings of a
satisfaction survey administered at the end of the study.
Methods
The last CTNS follow-up visit occurred in May 2007. A
manuscript describing the study results was submitted
in November 2007 and published in April 2008 [2]. The
material for dissemination of the results to the partici-
pants (a letter and two questionnaires) was prepared by
the Steering Committee. The letter on behalf of the
principal investigator and the study manager thanked
participants for their participation in the trial and
included a lay summary of trial results and conclusions.
Given the age of our patients and the objective of our
survey, we chose to use a questionnaire with a very sim-
ple structure, easy to complete and patient-friendly. The
questionnaires used in the survey were not formally vali-
dated but the letter and enclosed questionnaire were
shown to a small number of elderly patients to ensure
that they were clear and comprehensible (see Additional
file 1 and Additional file 2). The material was approved
by the Ethics Committee in Parma on April 10, 2008
and dissemination of results and questionnaires to sur-
viving CTNS participants began in mid-April 2008 and
completion of questionnaires continued until July 2009.
The study manager and an interviewer were responsible
for maintaining contact with the patients. The letter and
questionnaire 1 were initially mailed with a pre-paid
return envelope to 50 CTNS participants: since the
questionnaire seemed to be sufficiently clear to these
patients, we then proceeded with the dissemination of
the results. Letters were sent in batches until September
2008 to spread the workload generated by the letters.
The questionnaire included 8 closed questions designed
to evaluate participants’ level of satisfaction and under-
standing of the results and an offer to be informed
about individual treatment assignment. Participants
were invited to contact study staff if they required
further clarifications.
Upon receipt of a completed questionnaire, the study
manager telephoned the participants who indicated they
wanted to know whether they had been assigned the
vitamin-mineral supplement or the placebo. Patients
were offered the option of receiving this information on
the telephone or face-to-face at the clinic. In the latter
case they were offered an eye examination. During the
telephone contact or face-to-face at the clinic, the study
manager administered a second brief questionnaire (see
Additional file 3) and evaluated the understanding of
the randomisation process and the success of masking
by discussing with the participants whether they thought
they had taken the supplement or the placebo.
The study manager, with the help of an interviewer,
telephoned all participants who did not return the ques-
tionnaire: in some instances the letter and questionnaire
were resent to the participants, but generally partici-
pants who had not responded to the questionnaire pre-
ferred to be informed about the results directly by the
study manager or by one of the study ophthalmologists
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questionnaires were administered to the participant by
the study manager.
Analyses were carried out using the STATA statistical
package. Student’s t test was used for assessing differ-
ences between means and Chi-squared test for differ-
ences between proportions.
To assess whether participants had recognised their
treatment assignment, we compared the observed distri-
bution with a hypothetical distribution of equally likely
answers (p = 0.5) using a c
2 goodness of fit test.
Results
The letter describing the results of the trial was sent to
the 862 CTNS participants (average age 80.5 years,
range 68-89) who were alive at the end of the clinical
t r i a l( s e eF i g u r e1 ) .T h ef r e q u e n c yf i g u r e si nT a b l e1
were used to demonstrate the effect of treatment with
the dietary supplement on age-related cataract. Partici-
pants were told that the overall effect of the supplement
on the three types of cataract (nuclear, cortical, poster-
ior sub-capsular), when considered as a single disease,
was beneficial but when the opacities were considered
separately, a beneficial effect was noted for nuclear opa-
cities, an increase in risk was observed for posterior
sub-capsular opacities and no statistically significant
effect was observed for cortical opacities. Furthermore it
was specified that from a clinical viewpoint no relevant
differences between treatment groups were detected in
visual function performance or in the number of catar-
act surgeries. The letter indicated that, because of the
qualitatively different effect of treatment on the different
types of cataract, the investigators could not recommend
regular use of the supplement for the prevention of
cataract.
Forty-five of the 862 participants (5.2%) to whom the
results were sent died after the end of the study before
receiving the results. Eight hundred and seventeen parti-
cipants (94.8%) were alive at the time of the post trial
survey as verified in the National Health Service local
database.
Six hundred and ten of the 817 surviving participants
(74.7%) responded to the survey: of these 443 (72.6%)
completed the mailed questionnaire at home and 167
(27.4%) were administered the questionnaire at the clini-
cal centre during a scheduled visit or on the telephone.
Two hundred and seven subjects did not respond
(25.3%): 72 refused or were unable to complete the
questionnaire (41 not interested, 31 too ill) and 135
could not be contacted (inactive telephone number,
closed envelopes with results returned to clinic). Non-
responders were more likely than responders to be older
(p < 0.001), female (p = 0.002), unmarried (p = 0.002),
and to have undergone cataract surgery (p = 0.03)
(Table 2).
Overall 63.3% of the responders judged the description
of the results “very clear”, 31.3% “quite clear”,5 . 4 %
“unclear” or “do not know"; 46.4% of the responders
judged the results “very interesting”, 43.4% “quite inter-
esting”, 10.2% not interesting or “do not know” (Table 3).
If patients were subdivided according to selected mode of
communication with study staff (face-to-face, telephone,
no contact), the results were considered “very interesting”
by 52.4% of patients who attended a scheduled visit at the
clinical centre, by 47.4% of those who communicated
with study staff on the telephone and by 35.4% of those
who completed and returned the questionnaire without
requesting to communicate with study staff (p = 0.01).
After acknowledging the results 60.3% of the responders
expressed “satisfaction”, 17.2% “both satisfaction and
concern”,2 . 6 %“concern”, 19.9% “indifference” or “do not
know”.
To receive the results by mail was deemed “very
appropriate” by 74.3% of the responders and “quite
appropriate” by 19.2%, “not appropriate” or “do not
know” by 6.5%. However 299 (49%) of the responders
requested further clarifications from the study staff, e.g.
what type of cataract they had and how the trial conclu-
sions affected them as individuals.
The offer to reveal treatment assignment was accepted
by 480 of 610 (78.7%) responders. A total of 289 (60.2%)
participants chose to receive this personal information
on the telephone, 191 (39.8%) at the clinic during a
scheduled visit. Eighty-five responders (17.7%), accord-
ing to the study manager’s evaluation, did not recollect
or understand that assignment could be to one of two
interventions since they believed that the dietary supple-
ment was the only treatment offered. Of the 395 respon-
ders who clearly understood that assignment could be to
either treatment, 68 (17.2%) thought they had been
assigned to the vitamin mineral arm (79.4% were cor-
rect; c
2 goodness of fit test: p = 0.0006), 47 (11.9%) to
t h ep l a c e b oa r m( 5 9 . 6 %w e r ec o r r e c t ;c
2 goodness of fit
test: p = 0.46), 280 (70.9%) did not know. The subjects
who were not interested in being unmasked were older
(p = 0.04), had a lower level of education (p = 0.01) and
were assigned more frequently to placebo (p = 0.02)
(Table 2). After completion of the unmasking process,
the participants who had been assigned to placebo,
when asked “would you recommend to other persons to
take part in a study like CTNS ?”,a n s w e r e d :“definitely
yes” (95.6%) and “probably yes” (4.4%); while those
assigned to the vitamin/mineral supplement answered
“definitely yes” (94.3%) and “probably yes” (3.8%). The
satisfaction rating after unmasking was similar to that
prior to unmasking.
Williams et al. Trials 2011, 12:148
http://www.trialsjournal.com/content/12/1/148
Page 3 of 8Discussion
The World Medical Association Declaration of Helsinki
(October 2008) states that “at the conclusion of the
study, patients entered into the study are entitled to be
informed about the outcome of the study and to share
any benefits that result from it, for example, access to
interventions identified as beneficial in the study or to
other appropriate care or benefits” [7].
While participation in clinical studies is sometimes
motivated mainly by altruism[ 8 ] ,m o s ti n v e s t i g a t o r s
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Figure 1 Flow diagram.
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the results of clinical trials so that participants are not
treated as mere means to ends and to fulfil the ethical
obligation of respect for human dignity [9]. Although
there are no provisions in Italian law on whether and
how to provide study results, some investigators recog-
nise the need to communicate the therapeutic [6,8] or
preventative [10,11] findings of a study to participants,
even in studies such as CTNS which did not result in
any preventative or therapeutic recommendations [12].
Giving the participants the opportunity to understand
the contribution of the study to scientific knowledge can
be a way of highlighting the central role that they played
in the research project [13].
A year elapsed from the last follow-up visit to publica-
tion of the trial results in a peer-reviewed journal. More-
over the advanced age of the participants and difficulties
in finding participants who had changed their addresses
and telephone numbers complicated and delayed disse-
mination of results. This caused some CTNS participants
to complain about the delay in receiving the results. It is
generally accepted that results should be offered
promptly [9] and that it is critical to maintain contacts
with the participants until provision of results [14].
Table 1 Main results of the Italian-American clinical trial of nutritional supplements and age-related cataract, Parma,
1996-2008
RESULTS PROVIDED TO PARTICIPANTS
FREQUENCY OF EVENTS
PUBLISHED RESULTS[2]
ASSOCIATION BETWEEN TREATMENT AND CATARACT
EVENT
LENS EVENT Treatment in 510 participants Placebo in 510 participants
N. N. Hazard Ratio* 95% Confidence Interval
Cortical 96 118 0.78 0.60 - 1.02
Nuclear 84 118 0.66 0.50 - 0.88
PSC** 74 37 2.00 1.35 - 2.98
Cataract surgery 88 90 0.95 0.71 - 1.28
Any lens event*** 227 255 0.82 0.68 - 0.98
* Adjusted for age and type of opacity
** Posterior Sub-Capsular
*** Participants could have more than one event
Table 2 Characteristics of participants by response to dissemination of results and by acceptance of treatment
unmasking
SURVEY TREATMENT UNMASKING
CHARACTERISTICS Responders (n = 610) Non-responders (n = 207) c
2 test Accepted (n = 480) Declined (n = 130) c
2 test
%% P % % P
SEX
Male 53.3 41.1 51.5 60.0
Female 46.7 58.9 0.002 48.5 40.0 0.08
MARITAL STATUS
Married 78.9 67.1 78.7 79.2
Other 21.1 32.9 0.002 21.3 20.8 0.81
EDUCATION
Primary school 44.9 54.6 42.3 54.6
Middle school 25.8 21.3 28.1 16.9
High school 29.3 24.1 0.06 29.6 28.5 0.01
TREATMENT ASSIGNED
Placebo 48.8 51.7 46.5 57.7
Treatment 51.2 48.3 0.48 53.5 42.3 0.02
CATARACT SURGERY
Yes 21.2 28.5 21.5 20.0
No 78.8 71.5 0.03 78.5 80.0 0.72
AGE (MEAN)
Years 79.7 82.1 <0.001* 79.5 80.4 0.04*
* T test
Williams et al. Trials 2011, 12:148
http://www.trialsjournal.com/content/12/1/148
Page 5 of 8Efforts were made to present data in the letter so that
they were understandable to a lay population. For exam-
ple, instead of presenting hazard ratios and tests of sig-
nificance as was done in the published paper, absolute
frequencies of end-points in the study arms were pre-
sented. Interpreting the frequencies was made easier
because the same number of participants was rando-
mised to each arm of the study. About 94% of partici-
pants judged the presentation of results to be “very
clear” or “quite clear.” Only slightly fewer participants
found the results to be “very interesting” or “quite inter-
esting.” Although the results had no impact on clinical
practice, the positive public image of the study did not
seem to be affected. Almost all participants indicated
they would recommend that others take part in a study
such as CTNS. It is possible that, since 443 post-trial
questionnaires were completed at home by the partici-
pants and 167 were administered to participants at the
clinic, some elements of bias may have been introduced
in participants’ responses to post-trial questionnaire 1.
Table 3 Main responses to the post-trial questionnaire 1
QUESTIONS N. %
BEFORE DISCLOSURE
Do you think the description of the results of the study is clear? Very clear 386 63.3
Quite clear 191 31.3
Not clear 9 1.5
Do not know 24 3.9
TOTAL 610 100.0
Do you think the results of the study are interesting? Very interesting 283 46.4
Quite interesting 265 43.4
Not interesting 16 2.6
Do not know 46 7.6
TOTAL 610 100.0
What did you feel when you learned about the results of the study? Satisfaction 368 60.3
Concern 16 2.6
Both satisfaction and
concern
105 17.2
Indifference 68 11.2
Do not know 53 8.7
TOTAL 610 100.0
Do you think it is appropriate to receive the results of the study by letter? Very appropriate 453 74.3
Quite appropriate 117 19.2
Not appropriate 16 2.6
Do not know 24 3.9
TOTAL 610 100.0
Would you recommend to other persons to take part in a study like CTNS? Yes, definitely 554 90.8
Yes, probably 40 6.6
Probably not 4 0.6
Definitely not 1 0.2
Do not know 11 1.8
TOTAL 610 100.0
AFTER DISCLOSURE
Now that you know what treatment you took would you recommend to other persons to take part in a
similar study?
Yes, definitely 375 94.9
Yes, probably 16 4.1
Probably not 3 0.8
Do not know 1 0.2
TOTAL 395 100.0
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could be stressed [6] or even harmed [8,9] by provision
of personal and/or of general study results [15]. Possible
emotional harmful effects include: reliving difficult
moments, learning of being part of the “inferior” trial
arm or being at higher risk for a health-related problem
[12]. The risk of such harmful effects was not great in
CTNS because an effective surgical remedy is available
for age-related cataract and the intervention is known to
have essentially no side effects. However, the results of
CTNS could have been cause of concern because of the
increase in posterior sub-capsular opacities that was
unexpectedly noted among those in the active treatment
arm. In fact almost 20% of the participants expressed
some concern: 2.6% of the participants answered that
they experienced concern after receiving the results and
17.2% declared that they felt “both satisfaction and
concern”.
In order to respect the right of participants not to
know their treatment assignment, this information was
provided only to those who answered affirmatively to
our offer [15,16]. The participants who did not wish to
be informed about their assignment represent a self-
selected group to whom the second questionnaire was
not administered. Since no information was collected on
their understanding of the randomisation process and
on the success of masking, some element of selection
bias may have been introduced for responses to the sec-
ond questionnaire. Participants assigned to placebo were
significantly over-represented in the group who declined
unmasking (58% vs. 46%). The study tablets were manu-
factured to appear indistinguishable, and adherence to
treatment assignment was similar in the two arms over
the course of the trial. However the higher proportion
of participants in the vitamin-mineral arm who correctly
identified their assigned treatment (79.4%; c
2 goodness
of fit test: p = 0.0006) seems to suggest that they may
have recognised the supplement perhaps due to the
aroma or the taste of the tablets.
Being informed of their treatment assignment did not
seem to discourage participants in the placebo arm, most
of whom indicated that they would have certainly recom-
mended participation in a similar trial to other people.
We recognise the limitations of our post-trial survey,
which, by design, is subject to potential bias. We cannot
exclude the possibility that differences in the character-
istics of responders and non-responders (see age, sex
and lower education in Table 2) may have affected the
findings for our study population. Potential biases may
have been introduced by the questionnaires which were
not validated and did not use Likert scales.
The methods we used in communicating results from
the study and our findings may not be generalisable to
many other studies because ofs o m eu n i q u ef e a t u r e so f
our trial. We dealt with a non life-threatening condition
(cataract) for which there is an effective treatment and a
possible intervention (one-a-day vitamin) which had
essentially no adverse effects. In studies of more serious
conditions or studies that result in treatment recom-
mendations it may be necessary to disseminate the
results in a more timely fashion through immediate
direct contacts or group presentations. However, regard-
less of the nature of the study there is now general
recognition that investigators have an obligation to
share the results of studies with participants.
Conclusions
Dissemination of trial results is a process that should be
tailored to the context of each trial. It depends on the
condition of interest, on the population, on the inter-
ventions and on the outcomes, in particular on the
adverse events and on the trial results. In this paper we
have presented our experience in an elderly population,
affected by age-related cataract (a non-life threatening
disease), randomised to a one-a-day vitamin/mineral
supplement or placebo with few adverse events. The
trial results were not easy to communicate because of
the beneficial effect of supplement use on the primary
end-point of the study, the progression of any type of
opacity or cataract surgery, and the statistically signifi-
cant, but opposite, effects of supplement use on the two
most visually significant opacity subtypes. In general,
participants reported satisfaction with how the results
were disseminated and interest in the findings.
Additional material
Additional file 1: Letter to CTNS participants. Letter with trial results
sent to CTNS participants.
Additional file 2: Post-trial questionnaire 1. Questionnaire to assess
patient satisfaction and understanding of the results.
Additional file 3: Post-trial questionnaire 2. Questionnaire to assess
patient understanding of treatment assignment to supplement or
placebo and the success of masking.
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